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Background: Muir-Torre syndrome (MTS) is a rare inherited syndrome, with an
increased risk of sebaceous and visceral malignancy. Prior reports suggest screening
for mismatch repair (MMR) deficiency may be warranted in patients <50 years and
when sebaceous neoplasms are located on a non-head and neck location. Previously,
appropriate use criteria (AUC) were developed for clinical scenarios in patients
>60 years concerning the use of MMR protein immunohistochemistry (MMRP-IHC).
This analysis explores the appropriateness of testing in patients ≤60 years.
Methods: Panel raters from the AUC Task Force rated the use of MMRP-IHC testing
for MTS for previously rated scenarios with the only difference being age.
Results: Results verify the previously developed AUC for the use of MMRP-IHC in
neoplasms associated with MTS in patients >60 years. Results also show that in
patients ≤60 years with a single sebaceous tumor on a non-head and neck site,
MMRP-IHC testing should be considered. Testing can also be considered with a
2-antibody panel on periocular sebaceous carcinoma in younger patients.
Conclusions: Our findings align with known evidence supporting the need to incor-
porate clinical parameters in identifying patients at risk for MTS, with age being a fac-
tor when considering MMRP-IHC testing.
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1 | INTRODUCTION
Muir-Torre syndrome (MTS) is a rare inherited syndrome that was
first described independently in 1967 and 1968 by Dr. E.G. Muir and
Dr. Douglas Torre.1,2 MTS was later shown to be a clinical variant of
hereditary nonpolyposis colorectal cancer (HNPCC) and Lynch syn-
drome, the latter of which is caused by germline mutations in the
DNA mismatch repair (MMR) genes.3 MTS is characterized by the
presence of one or more sebaceous neoplasms or keratoacanthomas
and at least one HNPCC or Lynch syndrome-related internal malig-
nancy. The sebaceous lesions that can be seen in MTS include seba-
ceous adenoma, sebaceoma, sebaceous epithelioma, and sebaceous
carcinoma. The mean age of presentation of sebaceous lesions in
MTS is 53 years. Because the sebaceous lesions may precede inter-
nal malignancy, it has been suggested that dermatopathologists have
an opportunity to screen for MTS because microsatellite instability
secondary to germline mutations in the MSH2, MLH1, MSH6, and
PMS2 genes can be detected immunohistochemically by loss of
MMR protein expression.4–7 The most commonly used screening
antibodies include MSH2, MLH1, MSH6, and PMS2. It is debated in
the literature if MMR protein immunohistochemistry (MMRP-IHC)
testing should be performed on all sebaceous neoplasms, but most
studies suggest a targeted approach incorporating clinical parameters
to help dictate those neoplasms that should be tested.7 Recently, the
American Society of Dermatopathology (ASDP) published appropri-
ate use criteria (AUC) for the use of MMRP-IHC in neoplasms associ-
ated with MTS for patients more than 60 years old.8,9 AUC combines
scientific evidence with expert judgment to yield a statement of
appropriateness of a test in a specific clinical scenario.10 While
age >60 years was explored in the initial AUC given the greater
potential for misuse in this population, appropriateness ratings for
the test are lacking in younger patients that are diagnosed with
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neoplasms associated with MTS. This subsequent analysis explores
expert consensus (AUC) regarding MMRP-IHC testing in patients
aged ≤60 years.
2 | METHODS
Institutional review board approval was deemed unnecessary as the
study does not involve human subjects or include any interaction or
intervention with human subjects. Previously, the use of MMRP-IHC:
4-antibody panel (MSH2, MLH1, MSH6, and PMS2) and 2-antibody
panel (MSH2 and MLH1), in the screening for MTS was explored in
eight clinical scenarios (Table 1), which represent common situations
encountered in clinical practice.8,9 Each scenario was accompanied by
a set of definitions6,8,9,11 and independently reviewed for complete-
ness by dermatopathologists with expertise in the area and modified
accordingly (Table 2). Evidence on the use of MMRP-IHC was com-
piled (search years 2000 to 2016), provided to panel raters and is pub-
lished in the Journal of Cutaneous Pathology.7 In the current analysis,
expert panel raters (PRs) from the AUC Task Force of the ASDP were
surveyed and asked to independently rate the appropriateness of the
use of MMRP-IHC testing as a screening tool for MTS for the previ-
ously rated eight clinical scenarios, with the only difference being age.
As the ratings for the younger age group occurred almost immediately
following the third round for the previously developed AUC, each PR
was provided their score for the third rating round of the clinical sce-
narios for age >60 years. For each clinical scenario, PRs were asked if
age less than or equal to 60 years would change their prior rating. PRs
indicated “yes” or “no” to this question. If they answered “yes” to this
question, they were then asked to rank the appropriateness of the
TABLE 1 MTS appropriate use scores with 16 vs 12 panel raters
categorizing clinical scenarios for age >60 y
Clinical scenario 16 PR8,9 12 PR
4 Antibody panel
1. Periocular sebaceous
carcinoma
NC (3.5; 0/16 out) NC (3.3; 0/12 out;
SD = 2.9)
2. One sebaceous
tumor; head and
neck location
NC (5.1; 1/16 out) NC (5.9; 1/12 out;
SD = 2.1)
3. One sebaceous
tumor; non head and
neck location
NC (6.7; 1/16 out) NC (6.7; 1/12 out;
SD = 2.3)
4. Multiple sebaceous
tumors
UA (7.2; 0/16 out) UA (7.4; 0/12 out;
SD = 2.2)
5. Basal cell carcinoma
with sebaceous
differentiation
U (5.0; 0/16 out) U (5.3; 0/12 out;
SD = 1.6)
6. Keratoacanthoma
with sebaceous
differentiation
UA (7.1; 0/16 out) UA (7.3; 0/12 out;
SD = 1.9)
7. Cystic sebaceous
tumor
UA (7.3; 0/16 out) UA (7.3; 0/12 out;
SD = 2.0)
8. MTS associate
neoplasm and/or
visceral malignancy
UA (7.3; 1/16 out) UA (7.1; 1/12 out;
SD = 2.2)
2 Antibody panel
1. Periocular sebaceous
carcinoma
RA (3.0;
0/16 out)
RA (2.6; 0/12 out;
SD = 1.8)
2. One sebaceous tumor; head
and neck location
U (4.9;
0/16 out)
U (5.6; 1/12 out;
SD = 1.8)
3. One sebaceous tumor; non
head and neck location
UAU (6.9;
1/16 out)
NC (6.7; 1/12 out;
SD = 2.0)*
4. Multiple sebaceous tumors UA (7.2;
0/16 out)
UA (7.4; 0/12 out;
SD = 1.9)
5. Basal cell carcinoma with
sebaceous differentiation
U (4.6;
0/16 out)
U (4.9; 0/12 out;
SD = 1.9)
6. Keratoacanthoma with
sebaceous differentiation
UAU (6.6;
0/16 out)
UAU (6.6; 0/12
out; SD = 1.8)
7. Cystic sebaceous tumor UAU (6.9;
0/16 out)
UAU (6.8; 0/12
out; SD = 1.8)
8. MTS associate neoplasm
and/or visceral malignancy
UAU (6.9;
0/16 out)
NC (6.9; 1/12 out;
SD = 2.1)*
Note. Usually, appropriate indications (UA; mean’ scores of ≥7.0) are colored
dark green; usually appropriate to uncertain (“majority usually appropriate”)
indications (UAU; mean’ scores between 6.1 and 6.9 and SD <2.0) and
colored light green; rarely appropriate indications (RA; mean’ scores of ≤3.0)
are colored dark red; rarely appropriate to uncertain (majority rarely
appropriate) indications (RAU; mean’ scores between 3.1 and 3.9 and SD
<2.0); uncertain appropriateness indications (U; mean’ scores of ≥4.0
and ≤ 6.0 with a SD <2.0) are colored blue; no consensus (NC; mean’ scores
between 3.1 and 6.9 that had a SD ≥2.0) are colored white.
Abbreviations: MTS, Muir-Torre syndrome; PR, panel rater.
*Indicates difference noted between two groups.
TABLE 2 Definitions and clinical scenarios Muir-Torre syndrome
Definitions6,8,9,11:
• Age 60: There are some articles that suggest age 50 instead of
60 as a cut off, this may be because sebaceous neoplasms present
at a mean age of 53
• MTS associated sebaceous neoplasm: sebaceous adenoma,
sebaceoma, sebaceous epithelioma, sebaceous carcinoma
• MTS-associated neoplasm: MTS associated sebaceous neoplasms,
cystic sebaceous neoplasm, basal cell carcinoma with sebaceous
differentiation, keratoacanthoma with sebaceous differentiation
• MTS-associated visceral malignancy: colorectal adenocarcinoma
(most common), genitourinary carcinoma (second most common),
breast, hematologic, endometrial and gastric carcinoma (less common)
Clinical scenarios:
1. A patient with a periocular sebaceous carcinoma.
2. A patient with a single sebaceous tumor on the head and neck.
3. A patient with a single sebaceous tumor on a site other than the
head and neck.
4. A patient with multiple (greater than or equal to 2) sebaceous tumors.
5. A patient with a basal cell carcinoma with sebaceous
differentiation.
6. A patient with a keratoacanthoma with sebaceous differentiation.
7. A patient with a cystic sebaceous neoplasm.
8. A patient with a MTS-associated neoplasm and/or a personal
history of a MTS-associated visceral malignancy.
Abbreviation: MTS, Muir-Torre syndrome.
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test for that specific clinical scenario on a 9-point scale (Figure 1)
using their own best judgment and available literature. This was the
same scale used previously in the development of AUC.8,9 PRs did not
repeat the analysis for patients over the age of 60. As with the prior
study, PRs were instructed not to consider cost in their rating. In total,
12 of the prior 16 PRs completed the subsequent analysis.
The mean was calculated for both age groups (age >60 years and
age ≤60 years) based on the categorical assessment made by each PR
and then filtered by removing the highest and lowest scores to mini-
mize impact of outlying raters (mean’). The SD was also calculated for
each rating. Because not all the PRs completed the subsequent
assessment, notation was made as to the individual PR completing the
subsequent assessment. Only those PRs completing both assessments
were included in the current analysis. As with the prior assessment
scenarios with a mean’ >7 were categorized as “usually appropriate”.
Mean’ values between 6.1 and 6.9 and with a SD <2 were categorized
as majority usually appropriate (“usually appropriate to uncertain”).
Clinical scenarios with a mean’ ≤3 were categorized as “rarely appro-
priate”. Mean’ scores between 3.1 and 6.9 that had a SD <2.0 were
designated as majority rarely appropriate (“rarely appropriate to
uncertain”). Uncertain categorization was used for those clinical sce-
narios with a mean’ score of ≥4 and ≤6 with a SD of <2.0. Mean’
scores between 3.1 and 6.9 and with a SD ≥2 were defined as not
having reached consensus. Differences in appropriateness ratings, strati-
fied by patient age (<60 vs ≥60), were examined. In general, the catego-
ries ranked “uncertain” and those that did not reach consensus represent
areas where the literature may have been underdeveloped. Again, PRs
had the option to utilize the “out” option, which is not an acronym and
indicated that “assessment of appropriateness of test cannot be made
without direct communication with the clinician and furthermore the
appropriateness will change on a case by case basis depending on the
clinical information provided.” The use of this “out” option was recorded
and considered significant if used by greater than three PRs.
3 | RESULTS
Twelve PR responses were compared with prior published responses
from successive rounds of rating with 16 PRs that have been previ-
ously published (Table 1). Validating the previously developed AUC,
the rating categories did not change for the use of the 4-antibody
panel in the age greater than 60 years group with 12 vs 16 PRs
(Table 1). There were minor category changes in the 2-antibody panel
rating obtained with 12 vs 16 PRs (Table 1). One change was in clini-
cal scenario #3, which referred to testing of a patient with a seba-
ceous tumor on a non-head and neck site and the second in clinical
scenario #8, which refers to testing of a patient with a MTS associated
neoplasm and / or visceral malignancy. In both instances, the ratings
changed from “usually appropriate to uncertain” (majority usually
appropriate) to “no consensus”. These changes relate to minor differ-
ences in the SD likely resulting from fewer PRs. Table 1 highlights the
AUC scores obtained with 16 contrasted with 12 PRs.
In looking at the younger age group and use of the 4-antibody
panel (Table 3), there was a notable difference in categorical AUC
ranking for clinical scenario #3 - patient with a sebaceous tumor on a
F IGURE 1 Nine-point scale used in the ranking process for each clinical scenario. A score of 7 to 9 indicates the test is “usually appropriate”
with higher scores indicating greater agreement within this category. A score of 1 to 3 indicates the test is “rarely appropriate” in that specific
clinical scenario. A lower score within this range would indicate strength in conviction of the test being less appropriate. Scores in the range of
4 to 6 indicate “uncertain appropriateness” for ordering the test and generally indicate panel rater's assessment that there is a lack of scientific
evidence available to make a judgment either way
TABLE 3 MTS appropriate use scores for the 4-antibody panel
grouped by patient age
Clinical scenario Age >60 y Age ≤60 y
1. Periocular sebaceous
carcinoma
NC (3.3; 0/12 out;
SD = 2.9)
NC (4.0; 0/12
out; SD = 3.0)
2. One sebaceous tumor;
head and neck location
NC (5.9; 1/12 out;
SD = 2.1)
NC (6.0; 0/12
out; SD = 2.2)
3. One sebaceous tumor;
non head and neck
location
NC (6.7; 1/12 out;
SD = 2.3)
UA (7.1; 0/12
out; SD = 2.4)*
4. Multiple sebaceous
tumors
UA (7.4; 0/12 out;
SD = 2.2)
UA (7.6; 0/12
out; SD = 0)
5. Basal cell carcinoma with
sebaceous differentiation
U (5.3; 0/12 out;
SD = 1.6)
U (5.6; 0/12 out;
SD = 1.8)
6. Keratoacanthoma with
sebaceous differentiation
UA (7.3; 0/12 out;
SD = 1.9)
UA (7.6; 0/12
out; SD = 0)
7. Cystic sebaceous tumor UA (7.3; 0/12 out;
SD = 2.0)
UA (7.7; 0/12
out; SD = 0)
8. MTS associate neoplasm
and/or visceral
malignancy
UA (7.1; 1/12 out;
SD = 2.2)
UA (7.8; 0/12
out; SD = 2.1)
Usually appropriate indications (UA; mean’ scores of ≥7.0) are colored dark
green; usually appropriate to uncertain (“majority usually appropriate”)
indications (UAU; mean’ scores between 6.1 and 6.9 and SD <2.0) and
colored light green; rarely appropriate indications (RA; mean’ scores of ≤3.0)
are colored dark red; rarely appropriate to uncertain (majority rarely
appropriate) indications (RAU; mean’ scores between 3.1 and 3.9 and SD
<2.0); uncertain appropriateness indications (U; mean’ scores of ≥4.0
and ≤ 6.0 with a SD <2.0) are colored blue; no consensus (NC; mean’ scores
between 3.1 and 6.9 that had a SD ≥2.0) are colored white.
Abbreviation: MTS, Muir-Torre syndrome; y, years.
*Indicates difference noted between two groups.
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non-head and neck anatomic location. This scenario was deemed “no
consensus” in a patient >60 years of age; however, in younger
patients it was ranked by PRs as “usually appropriate”. Table 4 high-
lights the ratings for the use of the 2-antibody panel in younger
patients. Like the 4-antibody panel, clinical scenario #3 was ranked
“usually appropriate” to perform the test in patients ≤60 years of age.
Clinical scenario #1 was ranked as “no consensus” in patients
≤60 years of age. This is opposed to the ranking in older patients of
“rarely appropriate” to performing the test. Differences in rating were
also seen in clinical scenarios #2, #5, and #6, but these were second-
ary only to a slight increase in the SD. In addition, the calculated
mean’ in clinical scenarios #5 and #6 remained the same between
both age groups. Only rare PRs utilized the “out” option in the ratings
and did not reach significance, which was defined as >3 instances, for
any clinical scenarios. These results are summarized in Tables 3 and 4.
4 | DISCUSSION
The appropriateness method developed in the 1980s by RAND/UCLA
was established to explain the variation in utilization of medical
procedures and has a goal of improving the quality, efficiency, and
cost-effectiveness of health care. AUC are meant to determine when,
which, and how often a particular procedure or diagnostic test should
be performed in the context of: available scientific evidence, patient
characteristics, risk/benefit of treatment, and available health care
resources. AUC have been shown to improve diagnostic yield, clinical
outcomes, and reduce overall cost as well as resource utilization. AUC
are patient-centered and provide physicians with guidance for the use
of ancillary studies for a variety of patient scenarios that occur in clini-
cal practice. In general, AUC facilitate this decision-making by deriving
levels or categories of appropriateness based on examining the avail-
able clinical evidence and supplementing evidence with collective clin-
ical expertise and review from an expert panel of physicians.10
MTS and Lynch syndrome are caused by mutations in DNA MMR
genes.7 Review of the literature shows that MMR deficiency in seba-
ceous neoplasms ranges from 25% to 66% with the sensitivity of
MMRP-IHC testing being reported as high as 81%.7 However, MMRP-
IHC analysis is not without drawbacks. Studies with germline mutation
analysis show a high false-positive rate of MMRP-IHC in the range of
56%12 and a specificity of only 48%.13 This high false-positive rate and
low specificity have necessitated a more critical assessment of when to
screen MTS associated lesions before testing is initiated.
This study examines the effect of patient age on appropriateness rat-
ings with respect toMMRP-IHC analysis in clinical scenarios surrounding
MTS. Our previously published results for the use of a 4-antibody and
2-antibody panel in the screening for MTS in patients over the age of
60 years emphasizes that dermatopathologists should utilize a targeted
screening approach in situations when MMRP-IHC is being considered
and take into account other strong clinical indicators of MTS.8,9 The
result of this analysis validates the previously published AUC, highlight-
ing that even with fewer PRs AUC ratings for the use of MMRP-IHC in
patients over the age of 60 remain essentially unchanged. Moreover, this
study further supports the necessity of a tailored approach, which incor-
porates patient age, and strengthens the argument that clinical parame-
ters are essential in selecting individuals that would benefit from testing.
Previous studies have also suggested that age of presentation of seba-
ceous neoplasms is an important clinical parameter to consider in identi-
fying those patients at risk for MTS.12 Other studies investigating MMR
deficiency in sebaceous neoplasms have reported more frequent defi-
ciencies on non-head and neck sites.14,15 Thus, it is not surprising that a
significant categorical change occurred in the appropriateness ratings for
younger patients (≤60 years of age) in clinical scenario #3, which refers
to a non-head and neck site. This holds true whether screening is per-
formed with a 4-antibody panel or a 2-antibody panel. While all seba-
ceous tumors that have been associated with MTS were included in this
category, recent genetic data on extraocular sebaceous carcinoma sug-
gests that while microsatellite instability is not uncommon, many cases
are secondary to somatic rather than germlinemutations.16,17 In addition,
there was a categorical changewith the use of a 2-antibody panel in clini-
cal scenario #1, which explores the appropriate use of MMRP-IHC in
periocular sebaceous carcinoma. Appropriate ratings moved from “rarely
appropriate” to “no consensus”. Ocular sebaceous carcinoma is classically
considered a disease of the elderly with a median age of 73 years.18
TABLE 4 MTS appropriate use scores for the 2-antibody panel
grouped by patient age
Clinical scenario Age >60 y Age ≤60 y
1. Periocular sebaceous
carcinoma
RA (2.6; 0/12 out;
SD = 1.8)
NC (3.9; 0/12
out; SD = 2.1)*
2. One sebaceous tumor;
head and neck location
U (5.6; 1/12 out;
SD = 1.8)
NC (5.9; 1/12
out; SD = 2.4)*
3. One sebaceous tumor;
non head and neck
location
NC (6.7; 1/12 out;
SD = 2.0)*
UA (7.1; 0/12
out; SD = 2.7)*
4. Multiple sebaceous
tumors
UA (7.4; 0/12 out;
SD = 1.9)
UA (7.2; 0/12
out; SD = 1.8)
5. Basal cell carcinoma
with sebaceous
differentiation
U (4.9; 0/12 out;
SD = 1.9)
NC (4.9; 0/12
out; SD = 2.0)*
6. Keratoacanthoma with
sebaceous
differentiation
UAU (6.6; 0/12
out; SD = 1.8)
NC (6.6; 0/12
out; SD = 2.1)*
7. Cystic sebaceous tumor UAU (6.8; 0/12
out; SD = 1.8)
UAU (6.8; 0/12
out; SD = 1.9)
8. MTS associate neoplasm
and/or visceral
malignancy
NC (6.9; 1/12 out;
SD = 2.1)*
UA (7.0; 0/12
out; SD = 1.9)*
Usually appropriate indications (UA; mean’ scores of ≥7.0) are colored dark
green; usually appropriate to uncertain (“majority usually appropriate”)
indications (UAU; mean’ scores between 6.1 and 6.9 and SD <2.0) and
colored light green; rarely appropriate indications (RA; mean’ scores of ≤3.0)
are colored dark red; rarely appropriate to uncertain (majority rarely
appropriate) indications (RAU; mean’ scores between 3.1 and 3.9 and SD
<2.0); uncertain appropriateness indications (U; mean’ scores of ≥4.0
and ≤ 6.0 with a SD <2.0) are colored blue; no consensus (NC; mean’ scores
between 3.1 and 6.9 that had a SD ≥2.0) are colored white.
Abbreviation: MTS, Muir-Torre syndrome; y, years.
*Indicates difference noted between two groups.
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Consequently, its occurrence in a patient ≤60 years of age may have
been considered meaningful by some PRs. Recent sequencing data in
sebaceous carcinoma has suggested that half of lesions tested harbor a
somatic mutation in the PI3K signaling pathway and acquire recurrent
truncating mutations in transcription factor ZNF750.16,17 Still, many of
the lesions studied by Tetzlaff et al16 were older (median 63 years) and
age range was not presented for the sebaceous carcinomas studied in
North et al.17 As the literature continues to emerge and more informa-
tion is gained, these ratingsmay change. An update, which includes incor-
poration of recent literature, is already in progress.
Limitations of this study include that the UCLA/RAND methodol-
ogy used to develop these AUC requires a focus on appropriateness
without comparison. Accordingly, the results do not speak to which
antibody panel is better. The PRs were also instructed not to consider
cost in the analysis, which can be considered another limitation. Of
note, the nomenclature selected for the rating categories emphasizes
that the ultimate decision to perform the test should be made by the
physician considering the specifics of the patient. In addition, while
the PRs were provided specific instructions for rating there was likely
an assumption by PRs of no prior diagnosis of MTS. Lastly, one must
also recognize that AUC development is a lengthy process and in
areas where the literature is rapidly evolving, it can be challenging to
keep up to date.
In sum, this study helps to authenticate the previously developed
AUC for the use of MMR protein immunohistochemistry in neoplasms
associated with MTS in patients >60 years. In particular, highlighting
the importance of patient age and neoplasm location on appropriate
use scores when testing is being considered for cutaneous lesions
associated with MTS. Congruent with our prior study8,9 and the works
of Roberts et al12 and Singh et al13 these ratings lend further support
to a directed approach in selecting those individuals that could benefit
from MMRP-IHC testing and highlights the necessity of incorporating
clinical parameters.
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